Financial Performance - The company's operating revenue for Q1 2024 was CNY 204,929,240.40, representing a decrease of 26.68% compared to the same period last year[4] - The net profit attributable to shareholders for Q1 2024 was CNY 87,228,395.78, down 35.64% year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 76,157,757.92, a decline of 40.56% compared to the previous year[4] - The net cash flow from operating activities for Q1 2024 was CNY 133,086,579.74, reflecting a decrease of 25.28% year-over-year[4] - The basic earnings per share for Q1 2024 was CNY 0.18, down 37.93% from the same period last year[4] - Total operating revenue for Q1 2024 was CNY 204,929,240.40, a decrease of 26.7% compared to CNY 279,514,834.18 in Q1 2023[47] - Net profit for Q1 2024 was CNY 87,075,680.66, a decline of 35.7% from CNY 135,431,910.74 in Q1 2023[49] - Earnings per share for Q1 2024 were CNY 0.18, compared to CNY 0.29 in Q1 2023, indicating a decrease of 37.9%[50] - The company reported a total comprehensive income of CNY 90,397,978.13 for Q1 2024, compared to CNY 135,431,910.74 in Q1 2023, reflecting a decrease of 33.2%[50] Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,886, a decrease from the previous period[20] - The largest shareholder, Wuhan Huazhong Agricultural University Asset Management Co., Ltd., holds 16.73% of the shares[20] Assets and Liabilities - The total assets of the company as of the end of the reporting period were CNY 4,618,384,078.67, a slight decrease from CNY 4,671,249,471.01 in the previous period[26] - The company's fixed assets amounted to CNY 775,940,117.70, down from CNY 799,006,067.68 in the previous period[26] - Total liabilities decreased to ¥714,705,064.38 from ¥833,592,147.28 year-over-year[46] - The company’s total equity remained stable at ¥466,168,016.00[46] - Total assets at the end of the period were CNY 4,618,384,078.67, a decrease of 1.13% from the previous year[59] Cash Flow - Cash and cash equivalents increased to ¥800,292,120.31 from ¥581,740,744.51 year-over-year[43] - The net cash flow from operating activities was CNY 133,086,579.74, a decrease from CNY 178,103,336.61 in the previous period[53] - Total cash inflow from investment activities was CNY 446,189,764.61, compared to CNY 284,912,353.77 in the prior period[53] - The net cash flow from financing activities was negative at CNY -127,421,577.91, contrasting with a positive CNY 112,981,269.22 in the previous period[54] - The net increase in cash and cash equivalents was CNY 231,090,103.56, compared to CNY 270,276,842.01 in the prior period[54] - The total cash outflow from investment activities was CNY 220,764,662.94, down from CNY 305,720,117.59 in the prior period[53] Research and Development - The company obtained 44 new veterinary drug registration certificates, including 31 in collaboration with Huazhong Agricultural University and 12 with third-party partners[40] - Research and development expenses totaled CNY 19,840,800.13, representing 9.68% of operating revenue, an increase of 1.99 percentage points[59] - The company is focusing on laboratory research for multiple vaccines, including the live vaccine for porcine mycoplasma pneumonia, which generated approximately $538,276 in revenue[12] - Future outlook includes continued investment in research and development to enhance product offerings and address emerging market needs[4] Product Development and Market Expansion - The company is actively developing new products, including a recombinant canine parvovirus vaccine, which generated approximately $393,517 in revenue[22] - The company is expanding its market presence with clinical trials for rabies inactivated vaccines, which generated approximately $792,755 in revenue[23] - The company is exploring new strategies for market expansion through the development of innovative vaccine solutions, particularly in the swine and poultry sectors[4] - The total revenue from new veterinary drug registrations reached approximately $1.4 million across various products, indicating a strong pipeline[4] Challenges and Losses - The net profit attributable to shareholders decreased by 35.64% due to downstream supply chain pressures and a decline in operating revenue[37] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 40.56%, primarily driven by reduced operating revenue[37] - The diluted earnings per share also decreased by 37.93% due to the decline in operating revenue[37] - The company reported a loss of approximately $2.55 million from the study of Mycoplasma bovis competitive ELISA antibody test kits[9] - The indirect ELISA antibody test kit for African swine fever virus showed a loss of approximately $1.31 million, indicating challenges in this product line[18]

本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 4 月 22 日 证券代码：688526 证券简称：科前生物 公告编号：2024-023 武汉科前生物股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （二） 股东大会召开的地点：湖北武汉东湖新技术开发区高新二路 419 号科前 生物二楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 13 | | --- | --- | | 普通股股东人数 | 13 | | 2、出席会议的股东所持有的表决权数量 | 344,560,999 | | 普通股股东所持有表决权数量 | 344,560,999 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 74.1491 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 74.1491 | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 证券代码：688526 证券简称：科前生物 公告编号：2024-024 武汉科前生物股份有限公司 关于回购注销部分第一类限制性股票通知债权人的公告 由于公司本次回购注销部分第一类限制性股票将涉及注册资本 变更，根据《中华人民共和国公司法》等相关法律、法规的规定，公 司特此通知债权人。公司债权人自接到公司通知之日起 30 日内、未 接到通知的自本公告披露之日起 45 日内，均有权凭有效债权文件及 相关凭证要求公司清偿债务或者提供相应担保。 债权人未在规定期限内行使上述权利的，不会影响其债权效力， 公司将根据原债权文件的约定继续履行相关债务，并按法定程序继续 实施本次回购注销手续。 公司各债权人如要求公司清偿债务或提供相应的担保，可按如下 要求向公司申报： 一、通知债权人的原由 武汉科前生物股份有限公司（以下简称"公司"）于 2024 年 3 月 31 日召开第三届董事会第三十七次会议及第三届监事会第三十次 会议，分别审议通过了《关于回购注销 2021 年限制性股票激励计划 部 ...

北京市嘉源律师事务所 关于武汉科前生物股份有限公司 2023 年年度股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 二〇二四年四月 科前生物 2023 年年度股东大会 法律意见书 嘉源(2024)-04-273 受武汉科前生物股份有限公司(以下简称"科前生物"或"公司")委托, 北京市嘉源律师事务所(以下简称"本所")指派律师见证公司 2023年年度股 东大会,并依据《中华人民共和国公司法》《上市公司股东大会规则》《武汉科 前生物股份有限公司章程》(以下简称"《公司章程》")及《武汉科前生物股 份有限公司股东大会议事规则》的规定,就公司 2023 年年度股东大会(以下简 称"本次股东大会")的召集、召开程序、出席会议人员和召集人的资格、会议 的表决程序和表决结果等所涉及的有关法律问题出具见证意见如下: 一、本次股东大会的召集、召开程序 1. 公司第三届董事会第三十七次会议决议召开本次股东大会。本次股东大 会的召集人为公司董事会。 需 源律师事务所 IA YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI·深圳 SHENZHEN·香港 HONG ...

武汉科前生物股份有限公司 2023 年年度股东大会会议材料 证券简称：科前生物 证券代码：688526 武汉科前生物股份有限公司 2023 年年度股东大会 会议材料 2024 年 4 月 22 日 武汉科前生物股份有限公司 2023 年年度股东大会会议材料 武汉科前生物股份有限公司 2023 年年度股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司股东大会规则》以及《武汉科前生物股份有限公司章程》、《武汉科 前生物股份有限公司股东大会议事规则》等相关规定，特制定 2023 年年度股东 大会须知。 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进 入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示证券账户卡、身份证明文件或营业执照复印件（加盖公章）、 授权委托书等，上述登记材料均需提供复 ...

招商证券股份有限公司 关于武汉科前生物股份有限公司 2023 年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法 律、法规的规定，招商证券股份有限公司（以下简称"保荐机构"）作为武汉科前 生物股份有限公司（以下简称"科前生物"、 "公司"）持续督导工作的保荐机构， 负责科前生物上市后的持续督导工作，并出具本持续督导跟踪报告。 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 建立健全并有效执行持续督导工作制度，并针对 | 保荐机构已建立健全并有效执 | | 1 | | 行了持续督导制度，并制定了相 | | | 具体的持续督导工作制定相应的工作计划 | 应的工作计划 | | | 根据中国证监会相关规定，在持续督导工作开始 | 保荐机构已与科前生物签订《保 | | 2 | 前，与上市公司或相关当事人签署持续督导协 | 荐协议》，该协议明确了双方在 | | | 议，明确双方在持续督导期间的权利义务，并报 | 持续督导期间的权利和义务，并 | | | 上海证券 ...

一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本保荐机构及本人自愿接受中国证监会对保荐总结报告书相关事项进行 的任何质询和调查。 3、本保荐机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管 理办法》的有关规定采取的监管措施。 武汉科前生物股份有限公司 持续督导保荐总结报告书 招商证券股份有限公司 关于武汉科前生物股份有限公司 首次公开发行股票并在科创板上市持续督导保荐总结报告书 招商证券股份有限公司（以下简称"招商证券"或"保荐机构"）作为武汉 科前生物股份有限公司（以下简称"科前生物"或"公司"）首次公开发行股票 并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》等有关规 定，对科前生物首次公开发行股票并在科创板上市进行尽职推荐和持续督导，持 续督导期限自 2020 年 9 月 22 日至 2023 年 12 月 31 日。目前，持续督导期限已 满，本保荐机构根据《证券发行上市保荐业务管理办法》的有关规定对科前生物 出具保荐总结报告书，具体情况如下： ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688526 证券简称：科前生物 公告编号：2024-022 武汉科前生物股份有限公司 关于召开 2023 年度业绩暨现金分红说明会的公告 投资者可于 2024 年 04 月 15 日(星期一) 至 04 月 19 日(星期 五)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 wuhankqbio@kqbio.com 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 武汉科前生物股份有限公司（以下简称"公司"）已于 2024 年 4 月 2 日发布公司 2023 年度报告，为便于广大投资者更全面深入地了 解公司 2023 年度经营成果、财务状况，公司计划于 2024 年 04 月 22 日 上午 09:00-10:00 举行 2023 年度业绩暨现金分红说明会，就投 资者关心的问题进行交流。 一、 说明会类型 会议召开时间：2024 年 04 月 22 日(星期一) 上午 09:00-10:00 会议召开地点：上 ...

Investment Rating - The investment rating for the company is "Accumulate" [8]. Core Views - The company achieved a revenue of 1.064 billion yuan in 2023, representing a year-on-year growth of 6.3%. The net profit attributable to the parent company was 396 million yuan, down 3.3% year-on-year [2][8]. - The report highlights that the company is expected to benefit from a recovery in the breeding industry, with projected net profits for 2024, 2025, and 2026 being 518 million, 655 million, and 749 million yuan respectively [8]. - The report indicates that the company has made significant progress in its R&D pipeline across various segments, including vaccines for pigs and poultry [8]. Financial Summary - **Revenue and Profitability**: - Revenue for 2023 is projected at 1.064 billion yuan, with a growth forecast of 25.0% for 2024 and 17.9% for 2025 [2]. - The gross profit margin is expected to remain stable around 72.1% to 72.9% over the forecast period [2]. - The net profit margin for 2023 is 37.21%, with a slight decrease from the previous year [8]. - **Earnings Per Share (EPS)**: - The EPS is projected to increase from 0.85 yuan in 2023 to 1.61 yuan by 2026, reflecting a positive growth trajectory [2][8]. - **Return on Equity (ROE)**: - ROE is expected to improve from 10.3% in 2023 to 14.5% in 2026, indicating enhanced profitability and efficiency [2]. - **Valuation Metrics**: - The price-to-earnings (PE) ratio is projected to decrease from 22.8 in 2023 to 12.0 by 2026, suggesting that the stock may become more attractive over time [2][8]. - **Cash Flow**: - The company is expected to generate positive cash flows from operating activities, with projections of 538 million yuan in 2023 and increasing thereafter [2]. Market Data - The closing price of the stock was 19.34 yuan, with a total share capital of approximately 466.17 million shares [8]. - The report notes a significant decline in revenue and profit in the fourth quarter of 2023, indicating potential short-term challenges [8]. Investment Outlook - The report maintains a positive outlook on the company's future performance, driven by expected recovery in the breeding sector and ongoing advancements in product development [8].

Investment Rating - The report maintains a "Buy" rating for the company [3][31]. Core Views - The company achieved a revenue of 1.064 billion yuan in 2023, representing a year-on-year increase of 6.27%, while the net profit attributable to shareholders was 396 million yuan, a decrease of 3.32% year-on-year [1][22]. - The company continues to enhance its core competitiveness through technological innovation and increased R&D investment, with R&D expenses amounting to 88.51 million yuan, accounting for 8.32% of revenue [2]. - The company is expected to see significant growth in earnings per share (EPS) from 0.85 yuan in 2024 to 1.71 yuan in 2026, with corresponding dynamic price-to-earnings (PE) ratios decreasing from 15.6 to 11.5 [3][29]. Summary by Relevant Sections Financial Performance - In Q4 2023, the company reported a revenue of 237 million yuan, down 24.82% year-on-year, and a net profit of 39 million yuan, down 69.46% year-on-year [1]. - The company’s revenue from pig vaccines reached 973 million yuan in 2023, a year-on-year increase of 3.89%, driven by a 23% increase in sales volume of live pig vaccines [22]. R&D and Innovation - The company obtained two new veterinary drug registration certificates and seven clinical trial approvals during the reporting period, indicating a strong pipeline for future products [2]. - The company is advancing its research on non-epidemic vaccines, with a live vector vaccine submitted for emergency evaluation in December 2023 [2]. Earnings Forecast - The forecast for EPS is 1.26 yuan in 2024, 1.52 yuan in 2025, and 1.71 yuan in 2026, with expected revenue growth rates of 28.61%, 19.09%, and 13.57% respectively [3][29]. - The net profit attributable to shareholders is projected to grow significantly, with estimates of 589 million yuan in 2024, 709 million yuan in 2025, and 799 million yuan in 2026, reflecting growth rates of 48.82%, 20.25%, and 12.75% respectively [4][29].